Company Name	Sinovac Biotech Ltd.
Stock Code	NASDAQ: SVA
Industry	Biotech
Company Overview	Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps and canine rabies. In 2009, SINOVAC was the first company worldwide to receive approval for its H1N1 influenza vaccine, which it has supplied to the Chinese Government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government stockpiling program. SINOVAC has filed a new drug application with the China Food & Drug Administration for its proprietary enterovirus 71 vaccine, having been proven effective in preventing hand, foot and mouth disease in infants and children during its Phase III trial. The company is currently developing a number of new products including a Sabin-strain inactivated polio vaccine, pneumococcal polysaccharides vaccine, pneumococcal conjugate vaccine and varicella vaccine. SINOVAC primarily sells its vaccines in China, while also exploring growth opportunities in international markets. The Company has exported select vaccines to Mongolia, Nepal, the Philippines and Mexico, and was recently granted a license to commercialize its hepatitis A vaccine in Chile. For more information, please visit the Company's website at www.sinovac.com .
External Auditor	Marcum Bernstein & Pinchuk LLP
Law Firm	Latham & Watkins LLP
Transfer Agent	Pacific Stock Transfer Company
Investor Relations	ICR Inc.
Principal Executive Office	No. 39, Shangdi Xi Road, Haidian District, Beijing 100085, P.R.C.
Tel	+86-10-8289 0088
Fax	+86-10-6296 6910
Email	ir@sinovac.com
Website	www.sinovac.com